drugset
drugset / Trial / NCT01405885

A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza Virus

NCT01405885 ↗

Phase 1 Completed 116 enrolled Inovio Pharmaceuticals
Non-randomizedParallel-groupOpen-labelPrevention

Summary

This is a Phase I, parallel design open label study to evaluate safety, tolerability and immunogenicity of nine different formulation of two individual H1 and one H5 HA plasmid administered intradermally followed by electroporation in healthy adults

Timeline

Start
2011-05
Primary completion
2013-08
Completion
2013-08

Drugs

EvaluationDrugModalityDoseRoute
Subject INO-3401 Vaccine 0.9 mg Intravenous
Subject INO-3510 Unknown 0.3 mg Intravenous
Subject INO-3605 Unknown 0.45 mg Intravenous
Subject INO-3605 Unknown 0.9 mg Intravenous
Subject INO-3609 Unknown 0.3 mg Intravenous
Subject INO-3609 Unknown 0.45 mg Intravenous
Subject INO-3609 Unknown 0.9 mg Intravenous
Subject INO-3609 Unknown 1.8 mg Intravenous
Comparator Quadrivalent influenza vaccine Vaccine 0.5 ml Intramuscular

Indications

No indication recorded.